JP7167938B2 - Oral biofilm formation inhibitor and oral composition - Google Patents

Description

TECHNICAL FIELD The present invention relates to an oral biofilm formation inhibitor and an oral composition containing the same.

Oral diseases are caused by pathogenic bacteria, which colonize the oral cavity by forming plaque (dental plaque) on the tooth surface and exhibit pathogenicity. Therefore, plaque control is very important for prevention of oral diseases. Means for plaque control include suppression of plaque formation, removal, and sterilization, and among them, removal of plaque is considered to be important.
However, physical removal methods such as brushing, which is the basis of plaque removal, are limited in removal effect because there are places where it is difficult for the brush to reach, such as between teeth and periodontal pockets, and plaque is not formed. Techniques for preventing plaque formation are attracting attention, and the establishment of techniques for suppressing plaque formation is expected.
In recent years, plaque has been considered to be a biofilm consisting of bacterial aggregates and extracellular metabolites, etc., from the recognition that plaque is simply a stain of bacteria. It is also known to have physical resistance such as resistance to abrasion and resistance to peeling from the tooth surface. Under such circumstances, there is a demand for a control technique that prevents the formation of highly resistant biofilms.

As a technology for suppressing the formation of dental plaque, a technology for improving the retention of triclosan, an antibacterial agent (Patent Document 1; Japanese Patent Application Laid-Open No. 4-139118), has been proposed. It is hard to say that the effect on In addition, a technique for suppressing plaque adhesion using a special acrylic acid copolymer has also been proposed (Patent Document 2; JP-A-3-14512). It is not an effect of suppressing the formation of a strong barrier, and cannot be said to be a sufficient effect.

JP-A-4-139118 JP-A-3-14512 Japanese Patent Publication No. 7-29907 JP-A-2000-247851

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a novel oral biofilm formation inhibitor and an oral composition containing the same.

The present inventors have made intensive studies to achieve the above objects, and found that a polyacrylate having a weight average molecular weight of a specific value or less has the effect of suppressing the formation of oral biofilms, and excellent biofilms. It has been found that the effect of inhibiting biofilm formation is exhibited, and when a nonionic fungicide is used in combination, the action of the polyacrylate is enhanced, and the effect of inhibiting biofilm formation is remarkably improved. And, thereby, the polyacrylate, preferably by blending the combination system of the polyacrylate and the nonionic disinfectant into the oral composition, imparts an excellent biofilm formation inhibitory effect, In addition, the present inventors have found that they can provide a good feel during use, and have completed the present invention.

Polyacrylic acid or a salt thereof is known as a binder for oral compositions, but generally a crosslinked polyacrylic acid having a weight average molecular weight of 100,000 or more, usually about 300,000, or a salt thereof is used. ing. On the other hand, in the present invention, (a) a polyacrylate with a specific molecular weight having a weight average molecular weight of 20,000 or less, particularly a linear polyacrylate, does not form a biofilm in the oral cavity. It has been found that there is a hitherto unknown action and effect of suppressing the A particularly pronounced effect was obtained that could not be achieved when using non-morphic polyacrylic acid.
As shown in Comparative Examples in Tables 1 and 3 below, the effect of suppressing biofilm formation by sodium polyacrylate with a weight average molecular weight of 300,000 or polyacrylic acid with a weight average molecular weight of 6,000 is x. However, as shown in Examples in Tables 1 to 3, the effect of suppressing biofilm formation by the component (a) was all excellent, being ◯ or ⊚ or better.
In addition, nonionic fungicides are known to have a biofilm penetration sterilization effect, but an inhibitory effect on biofilm formation has not been recognized, and in fact, shown in Comparative Example 3 in Table 3 below. Thus, the biofilm formation inhibitory effect of isopropylmethylphenol was low. However, in the present invention, when the component (a) and the nonionic fungicide (b) are used in combination, both act synergistically, and the biofilm formation inhibitory effect is remarkable while suppressing the unpleasant odor caused by the component (a). (see Examples in Tables 1-3 below).
Although the details of the mechanism of action for suppressing biofilm formation in the present invention are not clear, due to the chemical action peculiar to the component (a), the component (a) acts on the biofilm itself, particularly the biofilm. It is speculated that the formation of a new biofilm is prevented by inhibiting the formation of a strong barrier during growth on the tooth surface.

In Patent Document 3 (Japanese Patent Publication No. 7-29907), about 2.5% of a polyacrylic acid polymer or polyacrylic acid copolymer having a weight average molecular weight of about 3,500 to 7,500 is used as an anticalculus agent. It is proposed to be blended in the oral composition in the above amounts. Patent Document 4 (Japanese Unexamined Patent Application Publication No. 2000-247851) proposes a tooth discoloration-inhibiting coating agent containing a specific anionic polymer compound and/or a polyacrylic acid polymer having a molecular weight of 20,000 or more as a salt thereof. This is the suppression of discoloration by coating, and the hydrophilicity of the tooth surface after coating makes it possible to easily remove the stained pellicle and prevent its accumulation. On the other hand, the present invention is (a) suppression of oral biofilm formation by a polyacrylic acid salt with a specific molecular weight, and such an effect is inferior to polyacrylic acid that is not in the form of a salt. It is excellent even if the amount of component (a) in it is 2% by mass or less.

Accordingly, the present invention provides the following oral biofilm formation inhibitor and oral composition.
[1]
(a) An oral biofilm formation inhibitor containing a polyacrylate having a weight average molecular weight of 1,000 or more and 20,000 or less.
[2]
(a) a polyacrylate having a weight average molecular weight of 1,000 or more and 20,000 or less, and (b) an oral biofilm formation inhibitor containing a nonionic bactericide.
[3]
(b) The oral biofilm formation inhibitor according to [2], wherein the component is one or more nonionic fungicides selected from isopropylmethylphenol, triclosan and thymol.
[4]
The oral biofilm formation inhibitor according to [2] or [3], wherein (a)/(b) is 0.01 to 200 as a mass ratio.
[5]
The oral biofilm formation inhibitor according to any one of [1] to [4], wherein the polyacrylate has a weight average molecular weight of 1,000 or more and 10,000 or less.
[6]
An oral composition containing (a) a polyacrylate having a weight average molecular weight of 1,000 or more and 20,000 or less, and (b) a nonionic bactericide.
[7]
The oral cavity composition according to [6], wherein the polyacrylate has a weight average molecular weight of 1,000 or more and 10,000 or less.
[8]
(b) The oral composition according to [6] or [7], wherein the component is one or more nonionic disinfectants selected from isopropylmethylphenol, triclosan and thymol.
[9]
The oral cavity composition according to any one of [6] to [8], wherein (a)/(b) is 0.01 to 200 as a mass ratio.
[10]
The oral composition according to any one of [6] to [9], containing 0.01 to 2% by mass of component (a) and 0.01 to 1% by mass of component (b).
[11]
The oral composition according to any one of [6] to [10], which is for oral biofilm suppression.
[12]
The oral composition according to any one of [6] to [11], which is a dentifrice composition.

INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide an oral biofilm formation inhibitor having an excellent effect of suppressing oral biofilm formation and an oral composition containing the same. Since the oral composition of the present invention has a high biofilm formation inhibitory effect and a good feeling when used, it can effectively inhibit biofilms, so it is suitable for preventing or inhibiting oral diseases such as periodontal disease. is.

The present invention will be described in further detail below. The oral biofilm formation inhibitor of the present invention is (a) a polyacrylate having a weight average molecular weight of 1,000 or more and 20,000 or less, and contains the above component (a) as an active ingredient.
The polyacrylate of component (a) has a weight average molecular weight (Mw) of 1,000 or more and 20,000 or less. In this case, the weight average molecular weight is 1,000 or more and 20,000 or less, preferably 10,000 or less, and more preferably 8,000 or less, from the viewpoint of biofilm formation suppression effect. When the weight average molecular weight is less than 1,000, the biofilm formation inhibitory effect is poor. If it exceeds 20,000, the effect of suppressing biofilm formation is reduced, and a sufficient effect cannot be obtained.

The weight average molecular weight was measured by GPC (gel permeation chromatography) under the method and measurement conditions described in Japanese Patent No. 5740859. Specifically, it is shown below (same below).
Method for measuring weight average molecular weight;
The weight average molecular weight is a value measured using a gel permeation chromatograph/multi-angle laser light scattering detector (GPC-MALLS) under the following conditions.
Mobile phase: 0.3M _NaClO4
NaN ₃ aqueous solution column: TSKgelα-M 2 pre-column: TSKguardcolumn α
Standard substance: Polyethylene glycol

(a) The polyacrylate of the component is preferably a linear polyacrylate from the viewpoint of the effect of suppressing biofilm formation.
The salt is preferably a monovalent salt, more preferably an alkali metal salt or an ammonium salt, still more preferably an alkali metal salt, and particularly preferably a sodium salt.
As such polyacrylic acid salts, commercial products sold by Polyscience Co., Ltd. or Toagosei Co., Ltd. can be used.
Specific commercial products include sodium polyacrylate (Mw: 1,000); linear, manufactured by Polyscience, sodium polyacrylate (Mw: 6,000); linear, manufactured by Toagosei Co., Ltd. , AC-10NP, AC-10NPD, Aron T-50, sodium polyacrylate (Mw: 8,000); linear, manufactured by Polyscience, sodium polyacrylate (Mw: 20,000); linear , Toagosei Co., Ltd., Aron A-20UN, etc. can be used.

The polyacrylate of component (a) has a lower weight average molecular weight than the crosslinked polyacrylate of the binder usually used in dentifrices, and is known as a binder. is different from
In place of the component (a), when a polyacrylate other than the component (a) is used, or when polyacrylic acid that is not in the form of a salt is used, the effect of suppressing biofilm formation is inferior, and further (b) Even if the ingredients are used in combination, the effect is inferior, and the unpleasant odor cannot be suppressed, resulting in a poor feeling of use, and the object of the present invention is not achieved.

In the oral biofilm formation inhibitor of the present invention, it is preferable to use (b) a nonionic bactericide in addition to the (a) component as an active ingredient. When the (a) and (b) components are used together, the biofilm formation inhibitory effect is further improved.
Some nonionic fungicides are known to have a biofilm penetration sterilization effect, and although it is recognized that it has a slight biofilm formation inhibitory effect, its effect was not sufficient. . On the other hand, when the component (b) is used in combination with the component (a), the biofilm formation inhibitory action is enhanced and manifested, and an unexpected and exceptional effect can be obtained. In addition, even if it is a fungicide, when a cationic fungicide is used together with the component (a), no enhancement of the biofilm formation inhibitory action is observed, which is an effect peculiar to the component (b).

(b) As nonionic fungicides, isopropylmethylphenol, triclosan, thymol can be used. These may be used alone or in combination of two. Isopropylmethylphenol is 4-isopropyl-3-methylphenol (Biosol (registered trademark)). Thymol is 2-isopropyl-5-methylphenol. Among them, isopropylmethylphenol (4-isopropyl-3-methylphenol) is preferable from the viewpoint of taste when used as an oral composition. These can use a commercial item.

Furthermore, (a)/(b), which indicates the quantitative ratio between component (a) and component (b), is preferably 0.01 to 200, more preferably 0.01 to 100, and still more preferably 0 as a mass ratio. 0.03 to 100, most preferably 0.03 to 80. Within this range, the biofilm formation inhibitory effect is more excellent.

The oral biofilm formation inhibitor of the present invention can be obtained by using component (a) alone as an active ingredient, preferably using component (b) in combination, and blending the above components. Furthermore, if necessary, other ingredients known for oral use may be included, and in this case, the known ingredients can be blended within a range that does not impair the effects of the present invention.

The oral composition of the present invention contains component (a) and component (b). Specific examples of oral compositions include paste-like, gel-like, or liquid dentifrices (toothpaste, gel-like dentifrice, liquid dentifrice, liquid dentifrice, etc.), mouthwashes, mouth sprays, coating agents, and patches. etc. can be suitably blended. Among them, it is suitable as a dentifrice composition, especially a toothpaste composition. Moreover, since it has an excellent biofilm inhibitory effect, it is suitable as an oral cavity composition for inhibiting oral biofilms.

In this case, in the present invention, when the components (a) and (b) are used together as an oral biofilm formation inhibitor, the specific ratio can be defined. Furthermore, in the present invention, the blending amounts of the component (a) and further the component (b) are preferably in the ranges described below from the viewpoint of the effect of suppressing biofilm formation and the feeling of use. It is preferred to use

The amount of component (a) is preferably 0.01 to 2% (% by mass, the same applies hereinafter), more preferably 0.01 to 1%, still more preferably 0.03 to 1%, and most preferably 0.01 to 1% of the total composition. Preferably it is 0.08 to 0.8%. Sufficient biofilm formation inhibitory effect is obtained as it is 0.01% or more. When it is 2% or less, the unpleasant odor derived from the component (a) can be sufficiently suppressed.

The content of component (b) is preferably 0.01 to 1%, more preferably 0.03 to 0.5% of the total composition. When it is 0.01% or more, a sufficient biofilm formation inhibitory effect can be obtained, and an unpleasant odor due to the component (a) can be sufficiently suppressed. If it is 1% or less, the offensive taste due to itself can be suppressed, and the bitter taste caused by the combined use of the components (a) and (b) can be sufficiently suppressed.

The composition for oral cavity of the present invention can further contain, as optional components, known components according to the dosage form and the like, if necessary. Optional components are preferably added within a range that does not impair the effects of the present invention. Specifically, dentifrices can contain abrasives, binders, thickening agents, surfactants, sweeteners, preservatives, coloring agents, fragrances, active ingredients, etc. These ingredients and water can be mixed. and can be manufactured.

Examples of abrasives include silica-based abrasives such as silicic anhydride, crystalline silica, amorphous silica, silica gel and aluminosilicate; tribasic calcium phosphate; quaternary calcium phosphate; calcium hydrogen phosphate anhydrate; and calcium hydrogen phosphate. Calcium phosphate abrasive such as dihydrate, zeolite, calcium pyrophosphate, calcium carbonate, sodium hydrogen carbonate, aluminum hydroxide, alumina, magnesium carbonate, magnesium tertiary phosphate, zirconium silicate, hydroxyapatite, synthetic resin abrasive is mentioned. These may be used alone or in combination of two or more. Among them, from the viewpoint of usability, silica-based abrasives such as silicic anhydride, which are inorganic abrasives, calcium phosphate-based abrasives, especially silicic anhydride. is preferred (the amount of abrasive compounded is usually 5 to 60%, and 10 to 55% in the case of toothpaste).

In particular, in the case of paste compositions such as toothpaste, as a binder, alginic acid derivatives such as sodium alginate and propylene glycol alginate, gums such as xanthan gum, tragacanth gum, gellan gum, karaya gum, gum arabic, etc. Crosslinked polyacrylates with a molecular weight of more than 20,000, carrageenan, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, sodium carboxymethylhydroxyethylcellulose, organic binders such as polyvinyl alcohol, carboxyvinyl polymer, and polyvinylpyrrolidone. agent, silica gel, aluminum silica gel, veegum, laponite, and other inorganic binders (usually 0.3-10%).

Furthermore, paste-like or liquid-like dentifrices in particular may contain one or more of sugar alcohols such as sorbitol, maltitol, lactitol, and erythritol, and polyhydric alcohols such as propylene glycol as thickeners (mixture amount is typically 5-70%).

Surfactants can be blended with anionic surfactants, nonionic surfactants, and amphoteric surfactants. These can use 1 type(s) or 2 or more types.
Examples of anionic surfactants include alkyl sulfates having 12 to 14 carbon atoms, particularly 12 alkyl groups, acyl amino acid salts, acyl taurine salts, and the like. The acyl group of the acylamino acid salt and acyl taurine salt preferably has 12 to 14 carbon atoms, preferably 12 carbon atoms.
Specific examples of alkyl sulfates include lauryl sulfate and myristyl sulfate, and examples of acyl amino acid salts include acyl glutamates such as lauroyl glutamate and myristoyl glutamate, acyl sarcosinates such as lauroyl sarcosinate, and acyl taurine. Salts include lauroyl methyl taurine salts. Salts are preferably alkali metal salts such as sodium salts and potassium salts. Alkyl sulfates, acyl sarcosine salts, and acyl taurine salts are particularly preferred. Among them, anionic surfactants having a hydrocarbon group of 12 carbon atoms (lauryl group) are preferred, and alkyl sulfates (sodium salts) are particularly preferred because they are superior in taste to other surfactants. .
Examples of nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene hydrogenated castor oil, polyoxyethylene ethers of glycerin esters, sucrose fatty acid esters, alkylols. amides, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, and glycerin fatty acid esters. Among these, polyoxyethylene alkyl ethers, polyoxyethylene hydrogenated castor oils, alkylolamides, and sorbitan fatty acid esters are preferred in terms of versatility. The polyoxyethylene alkyl ether preferably has an alkyl chain with 14 to 30 carbon atoms and an average added mole number of ethylene oxide (average added EO) of 3 to 30. Polyoxyethylene hydrogenated castor oil preferably has an average added EO of 10-100. The alkylolamide preferably has 12 to 14 carbon atoms in the alkyl chain. The sorbitan fatty acid ester preferably has 12 to 18 carbon atoms. The polyoxyethylene sorbitan fatty acid ester preferably has 16 to 18 carbon atoms in the fatty acid and 10 to 40 average added EO.
Amphoteric surfactants include acylaminoacetic acid betaine and fatty acid amidopropyl betaine having an acyl group of 12 to 14 carbon atoms. Acylaminoacetic acid betaine includes lauroyldimethylaminoacetic acid betaine, and fatty acid amidopropyl betaine includes coconut oil fatty acid amidopropyl betaine.

The content of the surfactant is usually 0.01-15%, especially 0.01-10%.
The blending amount of the anionic surfactant is preferably 0.1 to 3%, particularly 0.5 to 2%, and the blending amount of the nonionic surfactant is preferably 0.01 to 10%.

In the present invention, if a nonionic surfactant, especially polyoxyethylene hydrogenated castor oil, is used in combination with component (a), the smell and taste may deteriorate depending on the amount added, and the feeling of use may decrease. Addition of the above nonionic surfactant together with an anionic surfactant such as the above prevents deterioration of such odor and taste, and further improves the effect of suppressing biofilm formation without reducing the feeling of use.

Sweetening agents include saccharin sodium, stevioside, dipotassium glycyrrhizinate, perillartine, thaumatin, neohesperidyl dihydrochalcone, aspartylphenylalanine methyl ester. Preservatives include paraoxybenzoic acid esters and sodium benzoate.
Colorants include Blue No. 1, Yellow No. 4, and titanium dioxide.

Peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, lime. Oil, Lavender Oil, Rosemary Oil, Laurel Oil, Chamomile Oil, Caraway Oil, Marjoram Oil, Bay Oil, Lemongrass Oil, Origanum Oil, Pine Needle Oil, Neroli Oil, Rose Oil, Jasmine Oil, Iris Concrete, Absolute Peppermint , natural fragrances such as absolute rose, orange flower, and fragrances obtained by processing these natural fragrances (pre-reservoir cut, rear-reservoir cut, fractional distillation, liquid-liquid extraction, essence, powder perfume, etc.), and menthol, carvone, anethole, methyl salicylate, cinnamic aldehyde, 3-l-menthoxypropane-1,2-diol, linalool, linalyl acetate, limonene, menthone, menthyl acetate, N-substituted-paramenthane-3-carboxamide, Pinene, Octylaldehyde, Citral, Pulegone, Carbyl Acetate, Anisaldehyde, Ethyl Acetate, Ethyl Butyrate, Allylcyclohexane Propionate, Methyl Anthranilate, Ethyl Methyl Phenyl Glycidate, Vanillin, Undecalactone, Hexanal, Isoamyl Alcohol , hexenol, dimethyl sulfide, cyclotene, furfural, trimethylpyrazine, ethyl lactate, ethyl thioacetate, etc., strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, Known flavoring materials used in oral compositions, such as blended flavorings such as mixed fruit flavors and tropical fruit flavors, can be used, and are not limited to the flavorings in the examples.
Moreover, it is preferable to use 0.000001 to 1% of the entire composition of the perfume material. It is preferable to use 0.001 to 2.0% in the composition as a perfume for perfuming using the above perfume material.

Enzymes such as dextranase, mutanase, lysozyme, amylase, protease, lytic enzyme, and SOD (superoxide dismutase); alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate; Phosphate; Fluorides such as sodium fluoride and stannous fluoride; Anti-inflammatory agents such as tranexamic acid, epsilon aminocaproic acid, allantoin, allantoin chlorohydroxyaluminum, dihydrocholesterol, glycyrrhizic acid, glycyrrhetinic acid; potassium nitrate, aluminum lactate, etc. hypersensitivity improvers; zinc compounds such as glycerophosphate, chlorophyll, sodium chloride, zinc chloride, zinc oxide and zinc citrate; copper compounds such as copper gluconate and copper sulfate; water-soluble inorganic phosphorus such as sodium polyphosphate oxides; vitamins such as vitamin A, vitamin B group, vitamin C and vitamin E; crude drugs such as Phellodendron bark and tea. These active ingredients can be used singly or in combination of two or more, and can be blended in an effective amount within a range that does not interfere with the effects of the present invention.

The pH (25° C.) of the oral composition may be within a normal range, preferably pH 5-9, particularly pH 6-8. A known pH adjuster may be added to adjust the pH, for example, hydrochloric acid or an alkali metal hydroxide such as sodium hydroxide can be used.

EXAMPLES Hereinafter, the present invention will be specifically described by showing examples and comparative examples, but the present invention is not limited to the following examples. In the following examples, % indicates % by mass unless otherwise specified.
Also, the weight average molecular weight (Mw) was measured by GPC (gel permeation chromatography) under the same method and measurement conditions as above.

[Examples, Comparative Examples]
The types and amounts of polyacrylates shown in Table 1, and oral preparations containing the component (b) were prepared, and the biofilm formation inhibitory effect was evaluated by the following method. The results are also shown in Table 1.
Also, a dentifrice composition (toothpaste) having the composition shown in Tables 2 and 3 was prepared by a conventional method and filled in an aluminum laminate tube container. The effect of suppressing biofilm formation and the feeling of use (smell) were evaluated by the following methods. The results are shown in Tables 2 and 3 together.

(1) Method for evaluating biofilm formation inhibitory effect The following four types of bacteria were used to prepare model biofilms.
(i) Actinomyces viscosus ATCC43146
(ii) Fusobacterium nucleatum ATCC10953
(iii) Porphyromonas gingivalis ATCC33277
(iv) Veillonella parvula ATCC 17745
The bacteria (i), (ii), and (iii) are Toddhevit broth (Becton and Dickinson) culture medium. The bacteria of (iv) were cultured in a Toddhewitt broth (manufactured by Becton and Dickinson) containing 1.26% sodium lactate (manufactured by Sigma). The culture was carried out at 37° C. overnight anaerobic culture (80 vol % nitrogen, 10 vol % carbon dioxide, 10 vol % hydrogen).
The above-mentioned four strains of bacteria were inoculated into a Rotating Disk Reactor (fermenter) in which 3,000 mL of basal medium mucin culture medium (BMM) ^*1 had been placed in advance so as to obtain 1×10 ⁷ cfu/mL. In the culture tank, a hydroxyapatite plate (manufactured by HOYA Corporation, diameter φ7.0 mm × thickness 3.5 mm, abbreviated as HA plate) was treated for 4 hours with unstimulated human saliva filtered through a 0.45 μm filter. ) was set up as a carrier for model biofilm formation. In this state, culture was performed for 24 hours under anaerobic conditions (95 vol% nitrogen, 5 vol% carbon dioxide).
Next, under anaerobic conditions (95 vol% nitrogen, 5 vol% carbon dioxide), the BMM is replaced at a flow rate of 5 vol% / hour, and the test solution (in the case of oral preparations, artificial saliva 3-fold dilution , and BMM in the case of the control test) were continuously supplied at a flow rate of 5 vol%/hour for 10 days of continuous culture.
After the continuous culture treatment, the HA plate was removed, transferred to a 24-well multiplate (manufactured by Sumitomo Bakelite Co., Ltd.), and treated with 1 mL of phosphate buffered saline ^*2 (hereinafter abbreviated as PBS) 7 times. It was washed and immersed in a 0.1% crystal violet solution for 15 minutes to stain the biofilm formed on the HA plate surface. After removing the crystal violet solution and washing 5 times with 1 mL of PBS, the pigment was extracted with 2 mL of 30% acetic acid aqueous solution, the absorbance at 550 nm was measured, and the strength of the absorbance was taken as the amount of biofilm formation.
Taking the biofilm formation amount in the control test as 100, the biofilm formation amount ratio (%) when each test solution was added to it was calculated, and the biofilm formation inhibitory effect was evaluated.

Evaluation criteria ◎◎: less than 30% ◎: 30% or more and less than 50% ○: 50% or more and less than 70% △: 70% or more and less than 90% ×: 90% or more

^*1 ; Composition of BMM (indicated by mass in 1 liter)
Proteose peptone (manufactured by Becton and Dickinson):
4g/L
Tryptone (manufactured by Becton and Dickinson): 2 g / L
Yeast extract (manufactured by Becton and Dickinson):
2g/L
Mucin (manufactured by Sigma): 5 g / L
Hemin (manufactured by Sigma): 2.5 mg/L
Vitamin K (manufactured by Wako Pure Chemical Industries, Ltd.): 0.5 mg / L
KCl (manufactured by Wako Pure Chemical Industries, Ltd.): 1 g / L
Cysteine (manufactured by Wako Pure Chemical Industries, Ltd.): 0.2 g / L
Distilled water: Remainder (filled up to 1 L and autoclaved at 120°C for 20 minutes)

^*2 ；Composition of PBS (indicated by mass in 1 liter)
NaCl (manufactured by Wako Pure Chemical Industries, Ltd.): 8.0 g
KCl (manufactured by Wako Pure Chemical Industries, Ltd.): 0.2 g
Na ₂ HPO ₄ .12H ₂ O (manufactured by Wako Pure Chemical Industries, Ltd.): 3.63 g
KH ₂ PO ₄ (manufactured by Wako Pure Chemical Industries, Ltd.): 0.24 g
Distilled water: remainder (adjusted to pH 7.4 with 1N HCl and diluted to 1 L)

(2) Evaluation method of feeling of use Ten subject monitors placed 1 g of the dentifrice composition on a toothbrush and brushed for 3 minutes to wash the oral cavity, and evaluated the feeling of use (smell) according to the following rating criteria. . The average of 10 evaluation points was calculated and judged according to the following evaluation criteria.
Scoring criteria for feeling of use (smell) 4 points: no unpleasant odor in the oral cavity 3 points: slightly unpleasant odor in the oral cavity, but no problem level 2 points: unpleasant odor in the oral cavity 1 Point: Strong sense of unpleasant odor in the oral cavity Evaluation criteria for feeling of use (absence of odor) ◎: Average score of 3.5 points or more ○: Average score of 3.0 or more and less than 3.5 points △: Average score of 2. 0 points or more and less than 3.0 points ×: Average score less than 2.0 points

Details of raw materials used are shown below.
(a) sodium polyacrylate (Mw: 1,000)
Linear, manufactured by Polyscience (a) sodium polyacrylate (Mw: 6,000)
Linear, manufactured by Toagosei Co., Ltd., AC-10NP
(a) sodium polyacrylate (Mw: 8,000)
Linear, manufactured by Polyscience (a) sodium polyacrylate (Mw: 20,000)
Linear, manufactured by Toagosei Co., Ltd., Aron A-20UN
Sodium polyacrylate (Mw: 300,000, comparative product)
Crosslinked type, polyacrylic acid manufactured by Polyscience (Mw: 6,000, comparative product)
Linear, manufactured by Toagosei Co., Ltd., Aron A-10SL
(b) isopropylmethylphenol 4-isopropyl-3-methylphenol (Biozol),
Osaka Kasei Co., Ltd. (b) Thymol 2-isopropyl-5-methylphenol, Osaka Kasei Co., Ltd. (b) Triclosan BASF Co., Ltd.

Claims (10)

(a) an oral biofilm formation inhibitor containing a polyacrylate having a weight average molecular weight of 1,000 or more and 8,000 or less (excluding those containing hypochlorite) ; (a) polyacrylate having a weight average molecular weight of 1,000 or more and 8,000 or less, and (b) oral biofilm formation suppression containing one or more nonionic disinfectants selected from isopropylmethylphenol and thymol agents (excluding those containing hypochlorite) . The oral biofilm formation inhibitor according to claim 2 , wherein the component (b) is isopropylmethylphenol. The oral biofilm formation inhibitor according to claim 2 or 3, wherein (a)/(b) is 0.01 to 200 as a mass ratio. (a) a polyacrylate having a weight average molecular weight of 1,000 or more and 8,000 or less, and (b) an oral composition containing one or more nonionic disinfectants selected from isopropylmethylphenol and thymol ( However, oral compositions containing hypochlorite are excluded) . 6. The oral composition according to claim 5 , wherein component (b) is isopropylmethylphenol. The oral composition according to claim 5 or 6 , wherein (a)/(b) is 0.01 to 200 as a mass ratio. The oral composition according to any one of claims 5 to 7 , containing 0.01 to 2% by mass of component (a) and 0.01 to 1% by mass of component (b). The oral composition according to any one of claims 5 to 8 , which is for oral biofilm suppression. The oral composition according to any one of claims 5 to 9 , which is a dentifrice composition.